Gary Peters (D-MI)

BIOSECURE Act of 2025

S. 3469 · Senate bill Health

A Democratic bill with 1 Republican cosponsor · See the cosponsor

Last activity — Read twice and referred to the Committee on Homeland Security and Governmental Affairs.

In committee

Introduced and handed to a committee in the chamber it started in.

The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.

Its path through Congress

  1. Introduced
  2. In Committee

What this bill would do

The BIOSECURE Act of 2025 aims to prohibit federal agencies from contracting with certain biotechnology companies of concern. It restricts agencies from procuring biotechnology equipment or services from these entities and forbids the use of loan or grant funds for such purposes. The bill defines these companies based on their involvement in the industry and their connection to foreign adversaries or national security risks. Specific effective dates and rules for exceptions are established within the legislation. Agencies may grant specific waivers under certain conditions with approval from the Office of Management and Budget.

Yes

  • Scored +4

    Does this better protect the country from computer attacks?

    The bill enhances security by restricting the use of biotechnology equipment and services from companies linked to foreign adversaries.

  • Scored +3

    Does this give people more protection from unfair business practices?

    The bill protects consumer privacy by targeting entities that obtain human multiomic data without informed consent.

  • Scored +1

    Would veterans be better off under this, taking everything together?

    The bill includes specific exceptions to allow for the acquisition of health care services overseas for covered beneficiaries including veterans.

The opposite

  • Scored -2

    Does this make health care easier to get in general?

    The bill introduces prohibitions on certain biotechnology services which may limit the acquisition of overseas health care services.